menu
    • menu

    Company profile for Mallinckrodt Pharmaceuticals

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Mallinckrodt Pharmaceuticals is a multibillion dollar specialty biopharmaceutical company focused on our mission: Managing Complexity. Improving Lives. We provide medicines to address unmet patient needs, steming from nearly 150 years of using our unique strengths, experience and expertise to help improve people’s lives. Discover how our rich history of innovation and patient-centered solutions has helped influence our visio...
    Mallinckrodt Pharmaceuticals is a multibillion dollar specialty biopharmaceutical company focused on our mission: Managing Complexity. Improving Lives. We provide medicines to address unmet patient needs, steming from nearly 150 years of using our unique strengths, experience and expertise to help improve people’s lives. Discover how our rich history of innovation and patient-centered solutions has helped influence our vision for the future. Our strong ability to master and manage complexity is the key component in making high-quality products that provide value for patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Mallinckrodt PharmaceuticalsIreland Flag
    Country
    Country
    Ireland
    Address
    Address
    College Business & Technology Park Cruiserath, Blanchardstown Dublin 15
    Telephone
    Telephone
    +353 1 6960000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.mallinckrodt.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/mallinckrodt/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/mnk

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI Japan

    Not Confirmed

    envelop Contact Supplier

    CPhI Japan

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    This week, SpeakPharma interviews Pete Werth III, the new president of ChemWerth, a company that has been at the forefront of the generic pharmaceutical industry for over four decades. He shares his vision for ChemWerth, which includes his commitment to strengthening global manufacturing relationships, and enhancing supply chain resilience. Additionally, he highlights the key aspects of a successful drug master file (DMF). HIGHLIGHTS// Pete Werth III, the new president of ChemWerth/ vision for ChemWerth/ commitment to strengthening global manufacturing relationships/ key aspects of a successful drug master file Your father, Peter J. Werth, is recognized as one of the founders of the generic pharmaceutical industry, having built ChemWerth from the ground up over four decades ago. How do you view his legacy? As you take the helm, what key lessons or principles from his leadership do you intend to carry forward? My father, Peter J. Werth, is a true pioneer in the generic pharmaceutical industry. Over his 42‐year tenure, he not only built ChemWerth from a humble garage startup into a global leader in generic API development but also established standards that many in our industry now take for granted. Under his leadership, we filed our very first DMF in 1987 and have since achieved more than 500 DMF filings. With an average review cycle of just 0.79, we have been far outperforming the industry average of 2.5 cycles. His focus on quality, regulatory excellence, and a relentless commitment to customers’ success set the foundation for our reputation as a trusted supplier of over 500 APIs sourced from more than 30 cGMP-certified facilities worldwide. Equally inspiring is his dedication to nurture long-term, mutually beneficial relationships with manufacturing partners across the US, Europe, India, and China, as well as his passion for giving back to the community through philanthropic initiatives. As I take the helm, I intend to build on his guiding principles — sustaining our high standards of quality and compliance while pursuing innovation in regulatory strategy, diversifying our supply chain, and embracing new technologies and approaches to remain competitive in an evolving market. I will also strive to continue his legacy of mentorship, ensuring that our company culture remains rooted in integrity and diligence, with an unyielding focus on making safe, affordable medicines available worldwide. HIGHLIGHTS// trusted supplier of over 500 APIs/ 30 cGMP-certified facilities worldwide/ embracing new technologies and approaches to remain competitive What are your top priorities as the new president of ChemWerth? How do you plan to strengthen and expand relationships with manufacturers worldwide? My immediate priorities as the new president are twofold: to enhance the value we deliver to our customers and, to deepen our relationships with our manufacturing partners worldwide. We will further diversify our supply chain and broaden our product portfolio. Our expansion plans include upgrading equipment, and hiring additional highly skilled scientists, engineers, and GMP auditors. We will also leverage our proprietary product selection and regulatory submission processes. These processes help us get the regulatory filing right the first time, and allows us to be approved 44 percent faster than the industry average. This helps our customers gain a competitive edge in the market. In essence, by strengthening operational excellence and expanding our global network, we intend to continue the company’s long-standing commitment to customer success and process innovation. We plan to reinforce our long-standing relationships with our manufacturers — especially those in strategic markets like China and India — by helping our partners meet the highest standards of regulatory compliance and current good manufacturing practice (cGMP) quality. This balanced approach of strengthening existing partnerships while pioneering new ones is key to maintaining and growing our competitive edge. HIGHLIGHTS// diversify our supply chain and broaden our product portfolio/ commitment to customer success and process innovation/ filings approved 44 percent faster than the industry average When ChemWerth last spoke to PharmaCompass, there was a mention of investing millions of dollars in expanding manufacturing partnerships in China and India. Can you elaborate on the success of these partnerships, and how have they contributed to ChemWerth’s overall growth? Our strategic, multimillion-dollar investments in manufacturing partnerships are a cornerstone of our growth strategy. Over the past few years, these joint ventures have proven their worth by diversifying our supply base and mitigating the risk of global supply chain disruptions — a lesson that became all too clear during the Covid-19 pandemic. These investments are already paying dividends. They help us support manufacturers producing steroids, hormones, veterinary products, and large-volume APIs, while also accelerating the development of small-molecule inhibitors and new generic APIs. We have ensured that our partners are equipped with the latest equipment and trained personnel to meet cGMP standards. By partnering with facilities in these markets, we now have access to state-of-the-art production capabilities that enable us to produce a wider range of APIs at competitive costs. The success of these partnerships is evident in our ability to consistently file DMFs rapidly — often on the first cycle — and deliver affordable, high-quality medicines to patients worldwide. This supports our clients’ growth trajectory and has helped us expand into new markets. This strategy has reinforced our global footprint — supporting our presence in 38 countries with over 100 products — and positioned us well to capitalize on a global generic drug market projected to grow at a compounded annual growth rate of 5.4 percent from 2022 to 2030, to reach a size of US$ 671 billion by 2030. HIGHLIGHTS// strategic multimillion-dollar investments/ support manufacturers producing steroid, hormone, veterinary products/ development of small-molecule inhibitors and new generic APIs/ ensured partners are equipped with the latest equipment and trained personnel ChemWerth has an impressive track record, and an over 40-year relationship with the US Food and Drug Administration (FDA). What are the key aspects of a successful DMF? Are there specific challenges manufacturers face in preparing DMFs, and how does ChemWerth help them overcome these hurdles? ChemWerth’s record of filing over 500 DMFs in 38 countries reflects our commitment to excellence in regulatory compliance and quality management. A successful DMF is built on comprehensive documentation that rigorously follows cGMP guidelines, robust analytical validation, and detailed tracking of every step. Every DMF we file meticulously details the entire manufacturing process — from raw material acquisition to final batch production. This comprehensive approach ensures that our submissions meet the rigorous quality, safety, and efficacy standards expected by the FDA. Our team stays continuously updated on the evolving guidelines and protocols, which allows us to file DMFs that align with current FDA practices. We recognize that many manufacturers face challenges such as complex regulatory requirements, lengthy review cycles, and the need for precise coordination between various production stages. ChemWerth helps them overcome these hurdles by offering end-to-end regulatory support, detailed internal audits, and continuous training on cGMP and FDA requirements. Our efficiency is a critical competitive advantage. By receiving approvals 44 percent faster than the industry average, we help our customers get their products to market faster, resulting in larger market share and increased profits. HIGHLIGHTS// over 500 DMFs in 38 countries/ robust analytical validation/ end-to-end regulatory support What is your vision for ChemWerth over the next few years? How do you plan to navigate the challenges and opportunities in the generic pharmaceutical industry? I plan to continue to add value for our customers, and look for innovative ways to compete in today’s generic pharmaceutical landscape. At ChemWerth, our vision for the future is rooted in both our proud legacy and our relentless drive for innovation. We will further diversify our supply chain and expand our product portfolio. We have begun leveraging our expertise to supply APIs for biosimilars and new drug applications (NDAs), while maintaining our reputation for rapid regulatory approvals. With unwavering determination, we uphold our “First to Quality. Fast to Market.” approach — delivering high-quality APIs to customers worldwide while leveraging our expertise to give them a competitive edge in their markets. HIGHLIGHTS// supply APIs for biosimilars and NDAs/ give customers a competitive edge in their markets 

    Impressions: 817

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage

    Radio Compass
    12 Mar 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

    Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

    This week, we delve into molecular glue degraders (MGDs), one of the most promising frontiers in drug development. MGDs address a vast number of previously “undruggable” disease-causing proteins.Unlike traditional small molecule drugs that require specific binding pockets, MGDs function by enhancing protein-protein interactions. MGDs selectively target disease-causing proteins and an enzyme known as E3 ubiquitin ligase. By creating a binding interface between the two, MGDs  destroy the target proteins.Another kind of degraders are proteolysis targeting chimeras (PROTACs) that use a bifunctional approach — one binds the target proteins, and the other binds to an E3 ligases together. These degraders induce the degradation of specific proteins by using the cell’s natural ubiquitin-proteasome system (a process in cells where damaged or unneeded proteins are tagged by a small molecule called ubiquitin and then broken down by a structure called the proteasome so that cells stay healthy and function properly).MGDs constitute a rapidly growing market, where both the targeted protein degradation technologies and investment in research and development are witnessing growth.Currently, the most recognized molecular glues are the immunomodulatory imide drugs (IMiDs), such as thalidomide, lenalidomide and pomalidomide, which have been around for some time. According to GlobalData, lenalidomide generated over US$ 6 billion in sales in 2023, thereby demonstrating the commercial viability of this therapeutic approach.Lilly, AbbVie ink billion-dollar MGD deals; Biogen partners Neomorph; Pfizer, Triana ink collaborationThe MGD space has witnessed extraordinary deal-making activity over the recent months, with major pharmaceutical companies committing billions of dollars to secure access to novel MGD platforms and pipelines. This surge in investment reflects the industry’s growing confidence in the therapeutic potential of MGDs to address previously undruggable targets.This year has already seen two landmark deals. In February, Magnet Biomedicine entered into a collaboration and license agreement with Eli Lilly worth up to US$ 1.29 billion to discover and develop novel MGDs. This partnership leverages Magnet’s TrueGlue discovery platform and approach with Lilly’s expertise in the development of small molecule therapeutics. In January, AbbVie crafted a US$ 1.64 billion deal with molecular glue biotech Neomorph, combining AbbVie’s oncology and immunology drug development capabilities with Neomorph's leading molecular glue discovery platform.While oncology remains the primary focus, these collaborations are increasingly expanding into neurodegenerative diseases, immunological disorders, and other therapeutic areas. For instance, in October, Biogen and Neomorph announced a multi-target research collaboration to discover and develop MGDs for Alzheimer’s, rare neurological, and immunological diseases, potentially worth up to US$ 1.45 billion.October also saw Novartis sign a potential US$ 2.25 billion deal with Monte Rosa Therapeutics. The deal gives Novartis exclusive worldwide rights to develop, manufacture and commercialize multiple MGDs (including MRT-6160) for undruggable targets, including in the areas of immunology and inflammation, metabolism, and genetic diseases.Earlier in October, Triana Biomedicines and Pfizer entered into a research collaboration to discover novel MGDs for multiple targets across several disease areas, including oncology, with a total potential value of up to US$ 1.55 billion.And in August 2024, SEED Therapeutics entered into a strategic research collaboration with Eisai to discover and develop novel MGDs for neurodegenerative and oncological indications, potentially worth up to US$ 1.5 billion.BMS leads with three MGDs in late-stage trials; Monte Rosa’s MRT-2359 targets solid tumorsBristol Myers Squibb has established itself as a leader in the clinical development of MGDs with three products in late-stage development. These include a next-gen MGD mezigdomide (CC-92480), which is currently in phase 3 trials in combination with carfilzomib and dexamethasone for relapsed/refractory multiple myeloma. Another candidate is golcadomide, which is in late-stage clinical trials for high-risk first-line large B-cell lymphoma. And the third MGD in BMS’ portfolio is iberdomide, which has reached phase 3 development for multiple myeloma.Monte Rosa Therapeutics has made significant progress with MRT-2359, an investigational MGD that is currently in phase 1/2 clinical trials for the treatment of patients with MYC-driven solid tumors, including non-small cell lung cancer, small cell lung cancer, and high-grade neuroendocrine cancer. Myelocytomatosis or MYC is a gene which causes various solid tumors when overactive.MRT-2359 represents an important advancement in extending the molecular glue approach beyond hematological malignancies to solid tumors, which have historically proven more challenging to address with protein degradation strategies.Other significant early-stage candidates are Nested Therapeutics’ NST-628 and Plexium's PLX-4545. NST-628 relies on a novel mechanism of action in its category of RAS-MAPK inhibitors, and overcomes some traditional limitations in the treatment of cancers.PLX-4545 is Plexium’s first small molecule degrader program to enter clinical development. This potent and selective MGD of a classically undruggable transcription factor, also known as Helios (IKZF2), explores treating solid tumors. Transcription factors are proteins that regulate gene expression by binding to specific DNA sequences.Boehringer’s KRAS degrader advances PROTACs approach; Arvinas tests ARV-102 for neurodegenerative diseasesLike MGDs, PROTACs are also witnessing advancements in both R&D and dealmaking. For instance, BridGene Biosciences recently expanded its strategic collaboration with Galapagos to develop a selective oral SMARCA2 PROTAC in precision oncology. The SMARCA2 gene provides instructions for making one piece (subunit) of a group of similar protein complexes known as SWI/SNF complexes.In the clinical arena, Prelude Therapeutics announced a collaboration with Merck to evaluate PRT3789 in combination with Keytruda (pembrolizumab) in patients with SMARCA4-mutated cancers. PRT3789 is a potent and highly selective, first-in-class SMARCA2 degrader.On the molecular front, ACBI3, a novel pan-KRAS degrader developed through a collaboration between the University of Dundee and Boehringer Ingelheim, addresses a critical gap in cancer therapy by targeting 13 out of 17 prevalent KRAS mutants. KRAS mutation is a change in the KRAS gene, a common gene that can cause cancer. ACBI3’s development is a potential breakthrough for millions of cancer patients with KRAS-driven tumors.Vepdegestrant (ARV-471), a collaborative effort between Arvinas and Pfizer, remains the most advanced PROTAC candidate to date and has met its primary endpoint in a late-stage study in breast cancer patients with estrogen receptor 1 mutations.  Similarly, Arvinas’ ARV-102 became the first PROTAC to be tested in humans for neurodegenerative diseases, marking a significant milestone in addressing brain-related disorders.Our viewMGDs offer a new, and groundbreaking approach to treating cancers and various other diseases, thereby attracting substantial investments by major pharmaceutical companies. As clinical trials show encouraging results, we expect investments in the MGDs space to increase even further. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 531

    https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs

    #Phispers by PHARMACOMPASS
    27 Mar 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Mallinckrodt and Endo get a bump from tariffs in $6.7 billion merger
    Mallinckrodt and Endo get a bump from tariffs in $6.7 billion merger

    14 Mar 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/drugmakers-mallinckrodt-endo-merge-nearly-7-billion-deal-2025-03-13/

    REUTERS
    14 Mar 2025
    Share Share
    Mallinckrodt plc Reports Q4 and FY 2024 Results, 2025 Guidance
    Mallinckrodt plc Reports Q4 and FY 2024 Results, 2025 Guidance

    13 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mallinckrodt-plc-reports-fourth-quarter-and-fiscal-year-2024-financial-results-and-provides-2025-guidance-302400719.html

    PR NEWSWIRE
    13 Mar 2025
    Share Share
    Mallinckrodt plc Reschedules Q4 & FY 2024 Results to March 13
    Mallinckrodt plc Reschedules Q4 & FY 2024 Results to March 13

    10 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mallinckrodt-plc-reschedules-release-of-fourth-quarter-and-fiscal-year-2024-financial-results-to-thursday-march-13-2025-302397490.html

    PR NEWSWIRE
    10 Mar 2025
    Share Share
    CVC Completes Acquisition of Therakos from Mallinckrodt
    CVC Completes Acquisition of Therakos from Mallinckrodt

    02 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241202409570/en

    BUSINESSWIRE
    02 Dec 2024
    Share Share
    Mallinckrodt Completes Divestiture of Therakos® Business
    Mallinckrodt Completes Divestiture of Therakos® Business

    02 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mallinckrodt-completes-divestiture-of-therakos-business-302319183.html

    PR NEWSWIRE
    02 Dec 2024
    Share Share
    Mallinckrodt Presents Data on TERLIVAZ® for Hepatorenal Syndrome
    Mallinckrodt Presents Data on TERLIVAZ® for Hepatorenal Syndrome

    18 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mallinckrodt-presents-data-on-terlivaz-terlipressin-for-injection-in-patients-with-hepatorenal-syndrome-hrs-at-the-2024-american-association-for-the-study-of-liver-diseases-aasld-annual-meeting-302308532.html

    PR NEWSWIRE
    18 Nov 2024
    Share Share

    USDMF

    read-more
    read-more

    01

    6-beta-naltrexol Hydrochloride

    Ireland
    BePharma
    Not Confirmed
    arrow

    02

    Abx And Cbx Bonded Phase Silica Gels

    Ireland
    BePharma
    Not Confirmed
    arrow

    03

    Accurbron, S.r. (controlled Release ...

    Ireland
    BePharma
    Not Confirmed
    arrow

    04

    Acetaminophen

    Ireland
    BePharma
    Not Confirmed
    arrow

    05

    Acetaminophen Controlled-release Bea...

    Ireland
    BePharma
    Not Confirmed
    arrow

    06

    Acetaminophen Usp

    Ireland
    BePharma
    Not Confirmed
    arrow

    07

    Acetoxyacetyl Chloride

    Ireland
    BePharma
    Not Confirmed
    arrow

    08

    Acetoxyacetyl Chloride

    Ireland
    BePharma
    Not Confirmed
    arrow

    09

    Actifed S.a. Brand Of Pseudoephedrin...

    Ireland
    BePharma
    Not Confirmed
    arrow

    10

    Acyclovir Usp (micronized), Coded 25...

    Ireland
    BePharma
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    FDA

    read-more
    read-more

    01

    FDA Audited

    USA
    BePharma
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    BePharma
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2015-07-07

    Mallinckrodt Pharmaceuticals

    City : Cincinnati

    State : OH

    Country/Area : US

    Zip : 45237-1624

    District : CIN

    Center : CDRH

    Project Area : Compliance: Devices

    District Decision : No Action Indicated

    Inspection End Date : 2015-07-07

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    02

    FDA Audited

    USA
    BePharma
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    BePharma
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2015-07-07

    Mallinckrodt Pharmaceuticals

    City : Cincinnati

    State : OH

    Country/Area : US

    Zip : 45237-1624

    District : CIN

    Center : CDRH

    Project Area : Postmarket Assurance: Devices

    District Decision : No Action Indicated

    Inspection End Date : 2015-07-07

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    03

    FDA Audited

    USA
    BePharma
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    BePharma
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2014-07-25

    Mallinckrodt Pharmaceuticals

    City : Raleigh

    State : NC

    Country/Area : US

    Zip : 27616-3104

    District : ATL

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : No Action Indicated

    Inspection End Date : 2014-07-25

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    04

    FDA Audited

    USA
    BePharma
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    BePharma
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2014-06-18

    Mallinckrodt Pharmaceuticals

    City : Maryland Heights

    State : MO

    Country/Area : US

    Zip : 63043-3421

    District : KAN

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : No Action Indicated

    Inspection End Date : 2014-06-18

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    05

    FDA Audited

    USA
    BePharma
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    BePharma
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2014-06-18

    Mallinckrodt Pharmaceuticals

    City : Hazelwood

    State : MO

    Country/Area : US

    Zip : 63042-2513

    District : KAN

    Center : CDRH

    Project Area : Compliance: Devices

    District Decision : No Action Indicated

    Inspection End Date : 2014-06-18

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    06

    FDA Audited

    USA
    BePharma
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    BePharma
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2014-06-18

    Mallinckrodt Pharmaceuticals

    City : Hazelwood

    State : MO

    Country/Area : US

    Zip : 63042-2513

    District : KAN

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : No Action Indicated

    Inspection End Date : 2014-06-18

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    07

    FDA Audited

    USA
    BePharma
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    BePharma
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2014-06-18

    Mallinckrodt Pharmaceuticals

    City : Maryland Heights

    State : MO

    Country/Area : US

    Zip : 63043-3421

    District : KAN

    Center : CDRH

    Project Area : Compliance: Devices

    District Decision : No Action Indicated

    Inspection End Date : 2014-06-18

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    08

    FDA Audited

    USA
    BePharma
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    BePharma
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2014-06-12

    Mallinckrodt Pharmaceuticals

    City : Saint Louis

    State : MO

    Country/Area : US

    Zip : 63147-3457

    District : KAN

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : No Action Indicated

    Inspection End Date : 2014-06-12

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    09

    FDA Audited

    USA
    BePharma
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    BePharma
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2013-05-24

    Mallinckrodt Pharmaceuticals

    City : Saint Louis

    State : MO

    Country/Area : US

    Zip : 63147-3457

    District : KAN

    Center : CDER

    Project Area : Drug Quality Assurance

    District Decision : No Action Indicated

    Inspection End Date : 2013-05-24

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    10

    FDA Audited

    USA
    BePharma
    Not Confirmed
    arrow

    FDA Audited

    USA
    arrow
    BePharma
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2013-03-27

    Mallinckrodt Pharmaceuticals

    City : Maryland Heights

    State : MO

    Country/Area : US

    Zip : 63043-3421

    District : KAN

    Center : CDRH

    Project Area : Compliance: Devices

    District Decision : No Action Indicated

    Inspection End Date : 2013-03-27

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    EDQM

    read-more
    read-more

    01

    GMP Certified

    EU
    BePharma
    Not Confirmed
    arrow

    GMP Certified

    EU
    arrow
    BePharma
    Not Confirmed

    Mallinckrodt Pharmaceuticals

    Type : GMP Certificates

    Number : UK GMP 2042...

    EudraGMDP Key : 10803

    Country : U.S.A

    Issue Date :

    Post Code : 62246

    NCA Ref : 13486-MALLIN...

    City : GREENVILLE

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    02

    GMP Certified

    EU
    BePharma
    Not Confirmed
    arrow

    GMP Certified

    EU
    arrow
    BePharma
    Not Confirmed

    Mallinckrodt Pharmaceuticals

    Type : GMP Certificates

    Number : 2013/7285

    EudraGMDP Key : 7884

    Country : U.S.A

    Issue Date :

    Post Code : 27616

    NCA Ref : 7.8841257857...

    City : Raleigh

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    03

    GMP Certified

    EU
    BePharma
    Not Confirmed
    arrow

    GMP Certified

    EU
    arrow
    BePharma
    Not Confirmed

    Mallinckrodt Pharmaceuticals

    Type : GMP Certificates

    Number : 2012/5313

    EudraGMDP Key : 9182

    Country : U.S.A

    Issue Date :

    Post Code : 27616

    NCA Ref : 17236-MALLIN...

    City : RALEIGH

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    04

    GMP Certified

    EU
    BePharma
    Not Confirmed
    arrow

    GMP Certified

    EU
    arrow
    BePharma
    Not Confirmed

    Mallinckrodt Pharmaceuticals

    Type : GMP Certificates

    Number : UK GMP 2042...

    EudraGMDP Key : 10994

    Country : U.S.A

    Issue Date :

    Post Code : 13788

    NCA Ref : 12820-MALLIN...

    City : HOBART

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    05

    GMP Certified

    EU
    BePharma
    Not Confirmed
    arrow

    GMP Certified

    EU
    arrow
    BePharma
    Not Confirmed

    Mallinckrodt Pharmaceuticals

    Type : GMP Certificates

    Number : UK API 6538...

    EudraGMDP Key : 9182

    Country : U.S.A

    Issue Date :

    Post Code : 27616

    NCA Ref : 17236-MALLIN...

    City : RALEIGH

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Contact Mallinckrodt Plc and get a quotation

    Mallinckrodt Plc is a supplier offers 154 products (APIs, Excipients or Intermediates).

    Find a price of Paracetamol bulk with DMF, CEP, JDMF offered by Mallinckrodt Plc

    Find a price of Fentanyl bulk with CEP, JDMF offered by Mallinckrodt Plc

    Find a price of Fentanyl Citrate bulk with CEP, JDMF offered by Mallinckrodt Plc

    Find a price of Amphetamine bulk with DMF, CEP offered by Mallinckrodt Plc

    Find a price of Buprenorphine bulk with DMF, CEP offered by Mallinckrodt Plc

    Find a price of Buprenorphine Hydrochloride bulk with DMF, CEP offered by Mallinckrodt Plc

    Find a price of Codeine Phosphate bulk with DMF, CEP offered by Mallinckrodt Plc

    Find a price of Fentanyl Citrate bulk with DMF, JDMF offered by Mallinckrodt Plc

    Find a price of Ioversol bulk with DMF, JDMF offered by Mallinckrodt Plc

    Find a price of Methylphenidate Hydrochloride bulk with DMF, CEP offered by Mallinckrodt Plc

    Find a price of Naloxone Hydrochloride bulk with DMF, CEP offered by Mallinckrodt Plc

    Find a price of Naltrexone Hydrochloride bulk with DMF, CEP offered by Mallinckrodt Plc

    Find a price of Pethidine Hydrochloride bulk with DMF, JDMF offered by Mallinckrodt Plc

    Find a price of Sufentanil Citrate bulk with DMF, CEP offered by Mallinckrodt Plc

    Find a price of Calcium Stearate API bulk with CEP offered by Mallinckrodt Plc

    Find a price of Methadone Hydrochloride bulk with JDMF offered by Mallinckrodt Plc

    Find a price of Oxycodone Hydrochloride bulk with CEP offered by Mallinckrodt Plc

    Find a price of Amphetamine bulk with DMF offered by Mallinckrodt Plc

    Find a price of Amphetamine Aspartate bulk with DMF offered by Mallinckrodt Plc

    Find a price of Chlorpheniramine bulk with DMF offered by Mallinckrodt Plc

    Find a price of Cocaine Hydrochloride bulk with DMF offered by Mallinckrodt Plc

    Find a price of Codeine Sulfate bulk with DMF offered by Mallinckrodt Plc

    Find a price of Corticotropin bulk with DMF offered by Mallinckrodt Plc

    Find a price of Desmopressin Acetate bulk offered by Mallinckrodt Plc

    Find a price of Dexchloropheniramine Maleate bulk with DMF offered by Mallinckrodt Plc

    Find a price of Dexmethylphenidate bulk with DMF offered by Mallinckrodt Plc

    Find a price of Dextroamphetamine Saccharate bulk with DMF offered by Mallinckrodt Plc

    Find a price of Dihydrocodeine Tartrate bulk with DMF offered by Mallinckrodt Plc

    Find a price of Diphenoxylate Hydrochloride bulk with DMF offered by Mallinckrodt Plc

    Find a price of Fentanyl bulk with DMF offered by Mallinckrodt Plc

    Find a price of Gallium Chloride bulk with DMF offered by Mallinckrodt Plc

    Find a price of Hydrocodone Bitartrate bulk with DMF offered by Mallinckrodt Plc

    Find a price of Hydromorphone Hydrochloride bulk with DMF offered by Mallinckrodt Plc

    Find a price of Ibuprofen bulk with DMF offered by Mallinckrodt Plc

    Find a price of Indium Trichloride bulk with DMF offered by Mallinckrodt Plc

    Find a price of Iotalamic Acid bulk with DMF offered by Mallinckrodt Plc

    Find a price of Ioversol bulk with DMF offered by Mallinckrodt Plc

    Find a price of Leuprolide Acetate bulk offered by Mallinckrodt Plc

    Find a price of Levorphanol Tartrate bulk with DMF offered by Mallinckrodt Plc

    Find a price of Lisdexamfetamine Dimesylate bulk with DMF offered by Mallinckrodt Plc

    Find a price of Magnesium bulk with CEP offered by Mallinckrodt Plc

    Find a price of Methadone bulk with DMF offered by Mallinckrodt Plc

    Find a price of Methadone Hydrochloride bulk with DMF offered by Mallinckrodt Plc

    Find a price of Methylphenidate bulk with DMF offered by Mallinckrodt Plc

    Find a price of Morphine Sulfate bulk with DMF offered by Mallinckrodt Plc

    Find a price of Nalbuphine Hydrochloride bulk with DMF offered by Mallinckrodt Plc

    Find a price of Nalmefene Hydrochloride bulk with DMF offered by Mallinckrodt Plc

    Find a price of Naltrexone bulk with DMF offered by Mallinckrodt Plc

    Find a price of Naltrexone Methobromide bulk with DMF offered by Mallinckrodt Plc

    Find a price of Noscapine bulk with DMF offered by Mallinckrodt Plc

    Find a price of Octreoscan bulk with DMF offered by Mallinckrodt Plc

    Find a price of Opium bulk with DMF offered by Mallinckrodt Plc

    Find a price of Oxycodone Hydrochloride bulk with DMF offered by Mallinckrodt Plc

    Find a price of Oxymorphone bulk with DMF offered by Mallinckrodt Plc

    Find a price of Oxymorphone Hydrochloride bulk with DMF offered by Mallinckrodt Plc

    Find a price of Paracetamol bulk with DMF offered by Mallinckrodt Plc

    Find a price of Pentetic Acid bulk with DMF offered by Mallinckrodt Plc

    Find a price of Sodium Molybdate bulk with DMF offered by Mallinckrodt Plc

    Find a price of Sufentanil Citrate bulk with DMF offered by Mallinckrodt Plc

    Find a price of Thallium Chloride bulk with DMF offered by Mallinckrodt Plc

    Find a price of DCI-90 bulk with DMF offered by Mallinckrodt Plc

    Find a price of Konpappu L bulk with JDMF offered by Mallinckrodt Plc

    Find a price of Acetoxyacetyl Chloride bulk offered by Mallinckrodt Plc

    Find a price of Aciclovir bulk offered by Mallinckrodt Plc

    Find a price of Amphetamine bulk offered by Mallinckrodt Plc

    Find a price of Benzphetamine bulk offered by Mallinckrodt Plc

    Find a price of Butalbital bulk offered by Mallinckrodt Plc

    Find a price of Calcitonin bulk offered by Mallinckrodt Plc

    Find a price of Chlorzoxazone bulk offered by Mallinckrodt Plc

    Find a price of Codeine Sulfate bulk offered by Mallinckrodt Plc

    Find a price of Dextropropoxyphene bulk offered by Mallinckrodt Plc

    Find a price of Disodium Hydrogen Phosphate bulk offered by Mallinckrodt Plc

    Find a price of Docusate Potassium bulk offered by Mallinckrodt Plc

    Find a price of Docusate Sodium bulk offered by Mallinckrodt Plc

    Find a price of Doxylamine Succinate bulk offered by Mallinckrodt Plc

    Find a price of Exenatide bulk offered by Mallinckrodt Plc

    Find a price of Exenatide Synthetic bulk offered by Mallinckrodt Plc

    Find a price of Fentanyl Hydrochloride bulk offered by Mallinckrodt Plc

    Find a price of Ferrous Fumarate bulk offered by Mallinckrodt Plc

    Find a price of Gadoversetamide bulk offered by Mallinckrodt Plc

    Find a price of Gallium Chloride bulk offered by Mallinckrodt Plc

    Find a price of Hydrocodone Bitartrate bulk offered by Mallinckrodt Plc

    Find a price of Hydromorphone Hydrochloride bulk offered by Mallinckrodt Plc

    Find a price of Ibuprofen bulk offered by Mallinckrodt Plc

    Find a price of Indium bulk offered by Mallinckrodt Plc

    Find a price of Iotalamic Acid bulk offered by Mallinckrodt Plc

    Find a price of Isosorbide Dinitrate bulk offered by Mallinckrodt Plc

    Find a price of Lenperone bulk offered by Mallinckrodt Plc

    Find a price of Levorphanol Tartrate bulk offered by Mallinckrodt Plc

    Find a price of Lisdexamfetamine Dimesylate bulk offered by Mallinckrodt Plc

    Find a price of Methadone Hydrochloride bulk offered by Mallinckrodt Plc

    Find a price of Morphine Sulfate bulk offered by Mallinckrodt Plc

    Find a price of Nalbuphine Hydrochloride bulk offered by Mallinckrodt Plc

    Find a price of Naltrexone Hydrochloride bulk offered by Mallinckrodt Plc

    Find a price of Naltrexone Methobromide bulk offered by Mallinckrodt Plc

    Find a price of Natriuretic Peptide, Brain bulk offered by Mallinckrodt Plc

    Find a price of Noscapine bulk offered by Mallinckrodt Plc

    Find a price of Octreoscan bulk offered by Mallinckrodt Plc

    Find a price of Oxycodone Terephthalate bulk offered by Mallinckrodt Plc

    Find a price of Oxymorphone Hydrochloride bulk offered by Mallinckrodt Plc

    Find a price of Paracetamol bulk offered by Mallinckrodt Plc

    Find a price of Pemoline bulk offered by Mallinckrodt Plc

    Find a price of Pentazocine bulk offered by Mallinckrodt Plc

    Find a price of Perflutren bulk offered by Mallinckrodt Plc

    Find a price of Pethidine Hydrochloride bulk offered by Mallinckrodt Plc

    Find a price of Potassium Chloride bulk offered by Mallinckrodt Plc

    Find a price of Potassium Iodide bulk offered by Mallinckrodt Plc

    Find a price of Potassium Nitrate bulk offered by Mallinckrodt Plc

    Find a price of Pramlintide bulk offered by Mallinckrodt Plc

    Find a price of Propoxyphene Napsylate bulk offered by Mallinckrodt Plc

    Find a price of Pseudoephedrine bulk offered by Mallinckrodt Plc

    Find a price of Pseudoephedrine Hydrochloride bulk offered by Mallinckrodt Plc

    Find a price of Reserpine bulk offered by Mallinckrodt Plc

    Find a price of Selenium Methionine bulk offered by Mallinckrodt Plc

    Find a price of Silicon Dioxide API bulk offered by Mallinckrodt Plc

    Find a price of Silver Sulfadiazine bulk offered by Mallinckrodt Plc

    Find a price of Sodium Bitartrate bulk offered by Mallinckrodt Plc

    Find a price of Sodium Dihydrogen Phosphate Monohydrate bulk offered by Mallinckrodt Plc

    Find a price of Sodium Fluoride bulk offered by Mallinckrodt Plc

    Find a price of Sodium Iodide bulk offered by Mallinckrodt Plc

    Find a price of Sodium Perrhenate bulk offered by Mallinckrodt Plc

    Find a price of Sodium Sulfate bulk offered by Mallinckrodt Plc

    Find a price of Sodium Zomepirac bulk offered by Mallinckrodt Plc

    Find a price of Strontium Nitrate bulk offered by Mallinckrodt Plc

    Find a price of Tetrahydrocannabinol bulk offered by Mallinckrodt Plc

    Find a price of Thallium Chloride bulk offered by Mallinckrodt Plc

    Find a price of Theophylline bulk offered by Mallinckrodt Plc

    Find a price of Tolmetin Sodium bulk offered by Mallinckrodt Plc

    Find a price of Ziconotide bulk offered by Mallinckrodt Plc

    Find a price of PRODUCTION OF TALLOUS T1-201 CHL AT THE BURLINGAME, CA bulk offered by Mallinckrodt Plc

    Find a price of FACILITIES, PERSONNEL,AND G.O.P. FOR THE ST. LOUIS, MISSOURI PLANT bulk offered by Mallinckrodt Plc

    Find a price of MOLYDENUM 99:TECHNETIUM-99M bulk offered by Mallinckrodt Plc

    Find a price of HEXABRIX X-RAY CONTRAST MEDIA bulk offered by Mallinckrodt Plc

    Find a price of PROSAPTIDE bulk offered by Mallinckrodt Plc

    Find a price of INVESTIGATIONAL DRUGS bulk offered by Mallinckrodt Plc

    Find a price of FACILS & PERSONNEL FOR THE RAD PHARM INC CYCLOTRIN ON MAHLER RD. CA. bulk offered by Mallinckrodt Plc

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL AND GENERAL OPERATING PROCEDURES IN PETTEN, HOLLAND FACILITY. bulk offered by Mallinckrodt Plc

    Find a price of CYCLOTRON FACILITY-MARYLAND HEIGHTS, MO. bulk offered by Mallinckrodt Plc

    Find a price of MANUFACTURING FACILITY AT RALEIGH, NORTH CAROLINA bulk offered by Mallinckrodt Plc

    Find a price of FACILITIES, PROCEDURES AND PERSONNEL bulk offered by Mallinckrodt Plc

    Find a price of X-RAY CONTRAST MEDIA bulk offered by Mallinckrodt Plc

    Find a price of PROSAPTIDE TX 14(A), CODE 8200 bulk offered by Mallinckrodt Plc

    Find a price of BIOLOGICAL INDICATOR PROGRAM APPLIED MARYLAND HEIGHTS, MO PLANT SITE bulk offered by Mallinckrodt Plc

    Find a price of CODACET-60 (TM) bulk offered by Mallinckrodt Plc

    Find a price of SOD. IODIDE I-123 RADIOCHEM. SOL.-BURLINGAME,CA-(DMF FORMERLY RADPHARM bulk offered by Mallinckrodt Plc

    Find a price of FACILITIES-PERSONNEL-GEN. OPERATING PROCEDURES RALEIGH NC CHEM. PLANT bulk offered by Mallinckrodt Plc

    Find a price of MANUFACTURING & CONTROLS FOR LEVO ALPHA METHADYL ACETATE HYDROCHLORIDE bulk offered by Mallinckrodt Plc

    Find a price of GASTROMARK (FERUMOXSIL) BOWEL MARKER bulk offered by Mallinckrodt Plc

    Find a price of DEXTROCET-N2000 bulk offered by Mallinckrodt Plc

    Find a price of CT50034 bulk offered by Mallinckrodt Plc

    Find a price of MERCURY 195M/GOLD 195M GENERATORS-FACILS,METHDS,CONTRL FOR PREPARATION bulk offered by Mallinckrodt Plc

    Find a price of COMPAP (TM) bulk offered by Mallinckrodt Plc

    Find a price of Codeine Phosphate bulk offered by Mallinckrodt Plc

    Find a price of Dihydrocodeine Tartrate bulk offered by Mallinckrodt Plc

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search